October 7, 2019 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration Thermo Fisher Scientific’s forum focuses on strategies to expedite biotherapeutic development and commercialization LOGAN, Utah, Oct. 7, 2019 /PRNewswire/ — To discuss the future strategies of biologics development and commercialization, Thermo Fisher Scientific hosted the inaugural vertX Bioprocess Conference on Thursday, September 26... Read more

October 6, 2019 Microscopy Molecular Spectroscopy PR/Corporate

Conference Review: 16th Confocal Raman Imaging Symposium

The international chemical imaging community gathered once again in Ulm, Germany to share and discuss results, methods and technologies related to Raman microscopy. Almost one hundred attendees heard presentations arranged into distinct sessions under the headings: Nanotechnology and Low-dimensional Materials, Geosciences, Life Sciences, Applied Chemical Analysis, and Contributed Talks. Poster sessions provided a relaxed forum... Read more

October 2, 2019 Chromatography Clinical Research/Diagn. Lab Top-10 PR/Corporate

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China SANTA CLARA, Calif., October 2, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its PD-L1 IHC 22C3 pharmDx assay for use in China. The assay is now approved as... Read more

October 1, 2019 Acad, Gov/Utilities PR/Corporate

Luminex Receives FDA 510(k) Clearance for the ARIES® MRSA Assay

  AUSTIN, Texas, Oct. 1, 2019 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES® MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA)... Read more

September 30, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Basel, 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening... Read more

September 30, 2019 Life Science Tools PR/Corporate

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

Basel, 30 September 2019 Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal... Read more

September 28, 2019 PR/Corporate Product Launch

Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

Basel, 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival... Read more

September 27, 2019 Atomic Spectroscopy Bio/Pharma/CRO PR/Corporate

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more

September 27, 2019 PR/Corporate

We have issued "Annual Report 2019".

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more